CANADIAN EXPERT CONSENSUS ON USE OF HALOBETASOL PROPIONATE/TAZAROTENE LOTION FOR PLAQUE PSORIASIS

被引：0
|
作者：
Guenther, L. [1 ]
Prajapati, V [2 ,3 ]
Vender, R. [4 ]
Albrecht, L. [5 ]
Maari, C. [6 ]
Yanofsky, H. [7 ]
Gaudet, V [8 ]
Turchin, I [9 ]
机构：
[1] Guenther Dermatol Res Ctr, London, ON, Canada
[2] Univ Calgary, Dermatol Res Inst, Skin Hlth Wellness Ctr, Calgary, AB, Canada
[3] Prob Med Res, Calgary, AB, Canada
[4] Dermatrials Res Inc, Hamilton, ON, Canada
[5] Enverus Med Res, Surrey, BC, Canada
[6] Innovaderm Res, Montreal, PQ, Canada
[7] Howard Yanofsky Med Serv Inc, Montreal, PQ, Canada
[8] Canada Inc, Bausch Hlth, Laval, PQ, Canada
[9] Brunswick Dermatol Ctr, Fredericton, NB, Canada
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA56
引用
收藏
页码：S407 / S407
页数：1
相关论文
共 50 条
  • [21] Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities
    Tyring, Stephen
    Kircik, Leon H.
    Yamauchi, Paul
    Jacobson, Abby
    Lin, Tina
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (04) : 389 - 396
  • [22] Topical halobetasol propionate in the treatment of plaque psoriasis - A review
    Rivera, AM
    Hsu, S
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (05) : 311 - 316
  • [23] Halobetasol propionate 0.05 % cream: A guide to its use in the treatment of plaque psoriasis
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2013, 29 (4) : 102 - 107
  • [24] Halobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
    Cook-Bolden, Fran E.
    Hebert, Adelaide A.
    Guenthner, Scott T.
    Kang, Robert
    Martin, Gina
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 747 - 754
  • [25] Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion
    Shoen, Ezra
    Hou, Angela
    Zahn, Joseph
    Friedman, Adam
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (03) : 336 - 337
  • [26] A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis
    Radonjic, Aleksandar
    Evans, Emily L.
    DERMATOLOGIC THERAPY, 2019, 32 (04)
  • [27] Halobetasol and tazarotene: Further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis in a Hispanic population
    Yamauchi, Paul S.
    Bhatia, Neal D.
    Green, Lawrence J.
    Lin, Tina
    Martin, Gina
    Harris, Susan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB218 - AB218
  • [28] Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy
    Gold, Linda Stein
    Kircik, Leon
    Sugarman, Jeffrey
    Lin, Tina
    Pillai, Radhakrishnan
    Varughese, Johnson
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB69 - AB69
  • [29] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
    Gold, Linda Stein
    Lain, Edward
    Green, Lawrence J.
    Lin, Tina
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 815 - 820
  • [30] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
    Pariser, David M.
    Green, Lawrence J.
    Gold, Linda Stein
    Sugarman, Jeffrey L.
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 723 - 726
12345